Skip to main content
. Author manuscript; available in PMC: 2020 Feb 9.
Published in final edited form as: Clin Cancer Res. 2017 Dec 7;24(5):1038–1047. doi: 10.1158/1078-0432.CCR-17-2289

Figure 4. Survival comparisons among subjects with sEGFR, ALKr, or ROS1r mutations according to smoking status.

Figure 4.

A. Survival of never smokers without sEGFR-ALKr-ROS1r mutation, or with sEGFR-ALKr-ROS1r mutation who received targeted therapy.

B. Survival of former and current smokers without sEGFR-ALKr-ROS1r mutation, or with sEGFR-ALKr-ROS1r mutation who received targeted therapy.